Literature DB >> 24637996

Emerging role for bevacizumab in combination with chemotherapy for patients with platinum-resistant ovarian cancer.

Joyce F Liu1, Stephen A Cannistra.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24637996     DOI： 10.1200/JCO.2013.54.7299

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  SGO guidance document for clinical trial designs in ovarian cancer: a changing paradigm.

Authors:  Thomas J Herzog; Ronald D Alvarez; Angeles Secord; Barbara A Goff; Robert S Mannel; Bradley J Monk; Robert L Coleman
Journal:  Gynecol Oncol       Date:  2014-08-12       Impact factor: 5.482

Review 2.  Bevacizumab: a review of its use in advanced cancer.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2014-10       Impact factor: 9.546

Review 3.  New ways to successfully target tumor vasculature in ovarian cancer.

Authors:  Xiaoyun Yang; Fangrong Shen; Wei Hu; Robert L Coleman; Anil K Sood
Journal:  Curr Opin Obstet Gynecol       Date:  2015-02       Impact factor: 1.927

4.  CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer.

Authors:  Jung-Min Lee; Jane B Trepel; Peter Choyke; Liang Cao; Tristan Sissung; Nicole Houston; Minshu Yu; William D Figg; Ismail Baris Turkbey; Seth M Steinberg; Min-Jung Lee; S Percy Ivy; Joyce F Liu; Ursula A Matulonis; Elise C Kohn
Journal:  Front Oncol       Date:  2015-06-01       Impact factor: 6.244

5.  Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial.

Authors:  Dan P Stark; Adrian Cook; Julia M Brown; Michael D Brundage; Andrew C Embleton; Richard S Kaplan; Fharat A Raja; Ann Marie W Swart; Galina Velikova; Wendi Qian; Jonathan A Ledermann
Journal:  Cancer       Date:  2017-03-24       Impact factor: 6.860
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.